{"id":"W2229483068","doi":"10.1016/s0140-6736(15)01120-4","title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Royal Victoria Hospital; University of British Columbia; Hôpital Maisonneuve-Rosemont; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Refractory (planetary science); Internal medicine; Clinical endpoint; Clinical trial; Phases of clinical research; Surrogate endpoint; Proteasome inhibitor; Surgery; Gastroenterology; Oncology; Lenalidomide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07518314198563648,"score_gpt":0.3707187301208377,"score_spread":0.2955355881352012,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}